Exonate is an early stage biotech company spun out of the University of Nottingham, that specialises in the discovery and development of innovate therapeutics that alter mRNA splicing in areas of unmet medical need. Exonate’s lead program is in ophthalmology, focused on wet Age-Related Macular Degeneration, known as wet AMD , which is the leading cause of vision loss in people aged 60 and older.